Offstream
news

---

Changes

1. Trials for the drug developed by Novavax is shown to be 90% effective against COVID-19 and the Lineage B.1.1.7 variant of SARS-CoV-2.
   2021-03-31 03:06:19 (First version)
2. Trials for the drug developed by Novavax show that it is 90% effective against COVID-19 and the Lineage B.1.1.7 variant of SARS-CoV-2.
   2021-03-31 11:06:11 (Update)
3. Trials for the Novavax COVID-19 vaccine show that it is 90% effective against COVID-19 and the Lineage B.1.1.7 variant of SARS-CoV-2.
   (Current version)

---

Related

The U.S. CDC announces that it has recommended the Novavax COVID-19 vaccine for use in children between the ages of 12 and 17 years.
2022-08-22

Novavax says that it will pursue full approval for its COVID-19 vaccine during the second half of this year.
2022-02-28

The Australian Technical Advisory Group on Immunisation gives the final approval for use of the Novavax COVID-19 vaccine for people over the age of 18 years. The rollout of the vaccine will begin on February 21.
2022-01-24

South Korea authorizes the use of the protein-based Novavax COVID-19 vaccine for adults, making it the fifth vaccine to be approved for use in the country.
2022-01-12

The Ministry of Health and Family Welfare issues emergency use authorizations for the Covovax vaccine manufactured by the Serum Institute of India and the Corbevax vaccine. The ministry also issues an emergency use authorization for Merck & Co.'s anti-viral drug Molnupiravir.
2021-12-28

The Food and Drug Administration of the Philippines authorises emergency use of the Novavax COVID-19 vaccine, which will be included in the national vaccination program.
2021-11-17

Indonesia becomes the first country in the world to approve the protein-based Novavax COVID-19 vaccine, which will be manufactured by the Serum Institute of India.
2021-11-1

The Subject Expert Committee of the Central Drugs Standard Control Organisation will allow the Serum Institute of India to conduct trials of the Novavax COVID-19 vaccine in children between the ages of 7 and 11 years.
2021-09-28

Denmark confirms that it will purchase 280,000 doses of the Novavax COVID-19 vaccine for a total price of 37 million crowns ($5.84 million) or roughly $20.9 per dose as part of a European Union agreement with Novavax.
2021-08-11

Portugal reports its first two identified cases of COVID-19 infection with the Lineage P.1 variant of SARS-CoV-2, both of which were detected in the Lisbon metropolitan area.
2021-02-10